Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PA3U | ISIN: CA58410Q2036 | Ticker-Symbol: P731
Frankfurt
27.06.25 | 08:00
1,910 Euro
-6,37 % -0,130
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDEXUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MEDEXUS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur MEDEXUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoMedexus Pharmaceuticals is a buy, Research Capital says4
DoMedexus Pharmaceuticals Inc.: Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States380Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX executed...
► Artikel lesen
18.06.Medexus Pharmaceuticals Inc: Medexus to file fiscal 2025 results June 251
MEDEXUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
17.06.Medexus Pharmaceuticals Inc.: Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call340Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June...
► Artikel lesen
17.04.Medexus Pharmaceuticals Inc: Medexus completes listing agreement for Trecondyv1
17.04.Stocks in Play: Medexus Pharmaceuticals-
17.04.Medexus Pharmaceuticals Inc.: Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada400Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government of...
► Artikel lesen
08.04.Medexus is a "Strong Buy", Raymond James says1
07.04.Medexus Pharmaceuticals Inc: Medexus talks up market response to Grafapex1
07.04.Stocks in Play: Medexus Pharmaceuticals-
07.04.Medexus Pharmaceuticals Inc.: Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection251Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial...
► Artikel lesen
14.03.Stocks in Play: Medexus Pharmaceuticals-
14.03.Medexus Pharmaceuticals Inc: Medexus completes cancellation of Gleolan U.S. licence2
14.03.Medexus Pharmaceuticals Inc.: Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.297Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor...
► Artikel lesen
24.02.Medexus Pharmaceuticals Inc: Medexus's Grafapex for injection available in U.S.1
24.02.Medexus Pharmaceuticals Inc.: Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection474Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX (treosulfan) for Injection is now...
► Artikel lesen
07.02.Stifel cuts Medexus Pharma stock rating to Hold, target to C$3.453
06.02.Medexus Pharmaceuticals Inc: Medexus Pharmaceuticals halted at 7:31 a.m. PT3
06.02.Medexus Pharmaceuticals Inc: Medexus Pharmaceuticals to resume at 7:36 a.m. PT2
06.02.Medexus targets $100M annual revenue for GRAFAPEX within 5 years post-launch3
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1